Panavir, rectal suppositories 0.2mg, 5pcs

Composition

Active ingredient:

panavir® (polysaccharides of Solanum tuberosum shoots) 200 mcg;

Auxiliary substances:

confectionery fat or solid fat-1.0198 g;

paraffin — 0.09 g;

emulsifier T-2-0.09 g;

Pharmacological action

Panavir® is a purified extract of Solanum tuberosum plant shoots; the main Active ingredient is a hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, and uronic acids.

Panavir ® is an antiviral and immunomodulatory agent. Increases the body’s non-specific resistance to various infections and promotes the induction of interferons alpha and gamma by blood leukocytes.

In therapeutic doses, the drug is well tolerated.

Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies on laboratory animals, a negative effect on the reproductive function and development of the fetus was not established.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the test of pseudoallergic inflammatory response to concanavalin A.

Analgesic effect was shown on models of neurogenic pain and pain caused by the inflammatory process and thermal irritation.

It has an antipyretic effect.

Neuroprotective properties are shown on the model of Parkinsonian syndrome caused by systemic use of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

It has the ability to improve the function of the retina and optic nerve.

It has wound-healing properties in the model of gastric ulcer.

Indications

• herpesvirus infections of various localization, including recurrent genital herpes, herpes zoster and ophthalmic herpes;
• secondary immunodeficiency states against the background of infectious diseases;
• cytomegalovirus infection, including in patients with habitual miscarriage. It is used in women with chronic viral infection and interferon deficiency at the stage of preparation for pregnancy;
• papillomavirus infection (anogenital warts) – as part of complex therapy;
• tick-borne encephalitis-in order to reduce the viral load and relieve neurological symptoms (anisoreflexia, reduced reflexes, pain at the exit points of the cranial nerves, nystagmus) – as part of complex therapy;
• acute respiratory viral infections and influenza — as part of complex therapy.

Use during pregnancy and lactation

If it is necessary to use the drug during lactation, breastfeeding should be discontinued for the duration of the drug’s use.

Contraindications

• hypersensitivity;
• pregnancy;
• lactation;
• childhood.

Side effects

The drug is well tolerated, possible complications may be associated with individual intolerance and hypersensitivity to the components of the drug.

How to take, course of use and dosage

Rectally. For the treatment of herpesvirus infections and tick-borne encephalitis,1 suppository is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of cytomegalovirus and papillomavirus infections,1 suppository is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

For the treatment of acute respiratory viral infections and influenza,1 suppository is used at intervals of 24 hours for 5 days.

Special instructions

to prevent urogenital reinfection, simultaneous treatment of sexual partners is necessary. If there is no effect, the diagnosis should be confirmed.

Product form

rectal suppositories

Storage conditions

Store in a dry place, protected from light, at a temperature of 2 to 8 °C

Shelf life

3 years

Active ingredient

Panavir

Conditions of release from pharmacies

By prescription

Dosage form

rectal suppositories

Description

For adults as prescribed by a doctor, For adults

Indications

Immunodeficiency states, Herpes, Cytomegalovirus infection